Definitive Contract 75F40120C00195
Award Date
9/23/20
Potential Completion Date
9/29/23
Potential Value
$798K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Ann Arbor, MI 48109, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services Food and Drug Administration awarded a definitive cost-no-fee contract to the Regents of the University of Michigan for $1,482,306.00. The contract is to conduct research on the influence of raw materials, manufacturing variables, and storage conditions on the release performance of long-acting release microsphere products. The contract does not have a set-aside designation. The University of Michigan is a U.S. state government educational...
The Department of Health and Human Services' Food and Drug Administration (FDA) awarded a $1,151,037 firm-fixed-price contract to the Regents of the University of Michigan for the development of "SEAMLESS DESIGN FOR MULTICOMPONENT ENDPOINTS FOR DRUG DEVELOPMENT IN RARE DISEASES." This definitive contract, which has a completion date of September 29, 2026, does not have a set-aside designation. The University of Michigan, a prominent U.S. state government-owned educational...
The U.S. Food and Drug Administration (FDA) awarded a $1,000,000.00 definitive contract to the Regents of the University of Michigan to conduct research on the "Influence of Raw Materials Manufacturing Variables and Storage Conditions on Release Performance of Long Acting Release Microsphere Products." This is a cost-no-fee contract with a completion date of September 29, 2019. The University of Michigan is a U.S. Government Entity providing educational services and has extensive...
This is a $400,000.00 Firm Fixed Price Definitive Contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan. The contract is intended to advance the science of in vitro, animal model, pharmacokinetic studies, and/or real-world evidence studies to facilitate drug development, including studies focused on antimicrobial resistance and drug development for specific pathogens. This contract is not associated with a set-aside designation. The contract work...
This is a federal contract award from the Food and Drug Administration (FDA) to the Regents of the University of Michigan (University of Michigan) for the development of a "Wireless Pharmaceutical Analysis Device (WPAD) and Computational Model to Determine In Vivo Drug Dissolution in GI Tract for Distinguishing Meaningful Product Differences and Ensuring Bioequivalence." The contract is a definitive contract with a cost-no-fee pricing type and has a ceiling value of $6,343,667.39....
This is a $3,526,785.00 definitive, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, doing business as the University of Michigan, for Prediction of In Vivo Performance Analysis Services. The contract has no set-aside designation. The University of Michigan is providing a range of research and development services under this contract, including developing high-performance computational models to simulate small intestine...
The Food and Drug Administration (FDA) awarded a $997,608 firm-fixed-price contract to the Regents of the University of Michigan to conduct research and development on the characterization of Exparel, understanding of critical manufacturing process parameters, and characterization of drug release mechanisms in vitro and in vivo. This contract was awarded under a Broad Agency Announcement solicitation that the FDA renews annually to advance scientific knowledge in support of its mission to...
This federal contract, awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, is a $2,235,290.00 firm fixed-price definitive contract to conduct a comprehensive study on stimulant and opioid use and use disorder trajectories and associated consequences in U.S. adults. The contract does not have a set-aside designation. The University of Michigan, as the prime contractor, will leverage its extensive research capabilities to carry out this study. Two...
This is a $75,000.00 firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. Department of Health and Human Services, to the Regents of the University of Michigan. The contract does not have a set-aside designation. The University of Michigan is a leading public research institution that has previously held prime and subcontract awards with various federal agencies, including the Department of Veterans Affairs, to provide...
This is a $9,338,594.40 federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), part of the U.S. Department of Health and Human Services, to the Regents of the University of Michigan's Office of Research and Sponsored Projects (doing business as the University of Michigan). The contract is for biomedical research and development services, with a period of performance from September 30, 2004 to September 30, 2011. The contract type is a definitive contract with...